Four failure patterns, and how to design them out
Why Data & AI Portfolios Stall in Regulated Environments
A portfolio governance model for regulated environments: intake funnel, decision rights, benefit ownership, and the move into business-as-usual
Most data and AI portfolios do not fail because the technology does not work. They fail because no forum was ever obliged to choose.Trade-offs surfaced, and nobody had to resolve them.
Capacity is the binding constraint. Good ideas are plentiful; what runs short is the specific people who can move an idea through a regulated organisation and into stable operations – the ones who clear data access, validation evidence, and privacy review.
Approve work without accounting for that, and the portfolio becomes over-committed. Nothing fails outright. Initiatives drift, teams fragment, and the slippage becomes visible only once it is too late to trade anything off.
While this is written from a pharma and life sciences PoV, the patterns recur wherever validation, privacy, and quality sit on the critical path.


Most data and AI portfolios do not fail because the technology does not work. They fail because no forum was ever obliged to choose.Trade-offs surfaced, and nobody had to resolve them.
Capacity is the binding constraint. Good ideas are plentiful; what runs short is the specific people who can move an idea through a regulated organisation and into stable operations – the ones who clear data access, validation evidence, and privacy review.
Approve work without accounting for that, and the portfolio becomes over-committed. Nothing fails outright. Initiatives drift, teams fragment, and the slippage becomes visible only once it is too late to trade anything off.
While this is written from a pharma and life sciences PoV, the patterns recur wherever validation, privacy, and quality sit on the critical path.
Most data and AI portfolios do not fail because the technology does not work. They fail because no forum was ever obliged to choose.Trade-offs surfaced, and nobody had to resolve them.
Capacity is the binding constraint. Good ideas are plentiful; what runs short is the specific people who can move an idea through a regulated organisation and into stable operations – the ones who clear data access, validation evidence, and privacy review.
Approve work without accounting for that, and the portfolio becomes over-committed. Nothing fails outright. Initiatives drift, teams fragment, and the slippage becomes visible only once it is too late to trade anything off.
While this is written from a pharma and life sciences PoV, the patterns recur wherever validation, privacy, and quality sit on the critical path.
The Context
Most data and AI portfolios do not fail because the technology does not work. They fail because no forum was ever obliged to choose.Trade-offs surfaced, and nobody had to resolve them.
Capacity is the binding constraint. Good ideas are plentiful; what runs short is the specific people who can move an idea through a regulated organisation and into stable operations – the ones who clear data access, validation evidence, and privacy review.
Approve work without accounting for that, and the portfolio becomes over-committed. Nothing fails outright. Initiatives drift, teams fragment, and the slippage becomes visible only once it is too late to trade anything off.
While this is written from a pharma and life sciences PoV, the patterns recur wherever validation, privacy, and quality sit on the critical path.
The Context
Most data and AI portfolios do not fail because the technology does not work. They fail because no forum was ever obliged to choose.Trade-offs surfaced, and nobody had to resolve them.
Capacity is the binding constraint. Good ideas are plentiful; what runs short is the specific people who can move an idea through a regulated organisation and into stable operations – the ones who clear data access, validation evidence, and privacy review.
Approve work without accounting for that, and the portfolio becomes over-committed. Nothing fails outright. Initiatives drift, teams fragment, and the slippage becomes visible only once it is too late to trade anything off.
While this is written from a pharma and life sciences PoV, the patterns recur wherever validation, privacy, and quality sit on the critical path.

The Context
- Three initiatives approved in a quarter, all depending on the same two data engineers and the same validation queue. Each approval was sound on its own merits. The portfolio was never actually decided.
- Green for six consecutive weeks, then a single-step slip. Nobody is rewarded for escalating early, so the status holds while the assumptions underneath it drift.
- A solution the users call a success, the people funding it call unproven.
- Monitoring in place and alerts accumulating unread. Accountability for the outcome, the service, and the data definitions all defaulted to the last project team standing.
- Three initiatives approved in a quarter, all depending on the same two data engineers and the same validation queue. Each approval was sound on its own merits. The portfolio was never actually decided.
- Green for six consecutive weeks, then a single-step slip. Nobody is rewarded for escalating early, so the status holds while the assumptions underneath it drift.
- A solution the users call a success, the people funding it call unproven.
- Monitoring in place and alerts accumulating unread. Accountability for the outcome, the service, and the data definitions all defaulted to the last project team standing.
- Three initiatives approved in a quarter, all depending on the same two data engineers and the same validation queue. Each approval was sound on its own merits. The portfolio was never actually decided.
- Green for six consecutive weeks, then a single-step slip. Nobody is rewarded for escalating early, so the status holds while the assumptions underneath it drift.
- A solution the users call a success, the people funding it call unproven.
- Monitoring in place and alerts accumulating unread. Accountability for the outcome, the service, and the data definitions all defaulted to the last project team standing.
Four Patterns We See Repeatedly
- Three initiatives approved in a quarter, all depending on the same two data engineers and the same validation queue. Each approval was sound on its own merits. The portfolio was never actually decided.
- Green for six consecutive weeks, then a single-step slip. Nobody is rewarded for escalating early, so the status holds while the assumptions underneath it drift.
- A solution the users call a success, the people funding it call unproven.
- Monitoring in place and alerts accumulating unread. Accountability for the outcome, the service, and the data definitions all defaulted to the last project team standing.
Four Patterns We See Repeatedly
- Three initiatives approved in a quarter, all depending on the same two data engineers and the same validation queue. Each approval was sound on its own merits. The portfolio was never actually decided.
- Green for six consecutive weeks, then a single-step slip. Nobody is rewarded for escalating early, so the status holds while the assumptions underneath it drift.
- A solution the users call a success, the people funding it call unproven.
- Monitoring in place and alerts accumulating unread. Accountability for the outcome, the service, and the data definitions all defaulted to the last project team standing.
Four Patterns We See Repeatedly
- A two-lane intake funnel, with a fast-track for mandatory work
- Decision rights split across Decision Board, Steering Committee, and operational reporting
- Three separate funding models for different business realities
- A benefit framework covering financial, capacity, and risk/quality outcomes, with worked kill triggers
- A five-point handover checklist for the move into business-as-usual


- A two-lane intake funnel, with a fast-track for mandatory work
- Decision rights split across Decision Board, Steering Committee, and operational reporting
- Three separate funding models for different business realities
- A benefit framework covering financial, capacity, and risk/quality outcomes, with worked kill triggers
- A five-point handover checklist for the move into business-as-usual
- A two-lane intake funnel, with a fast-track for mandatory work
- Decision rights split across Decision Board, Steering Committee, and operational reporting
- Three separate funding models for different business realities
- A benefit framework covering financial, capacity, and risk/quality outcomes, with worked kill triggers
- A five-point handover checklist for the move into business-as-usual
What You'll Discover in the Whitepaper
- A two-lane intake funnel, with a fast-track for mandatory work
- Decision rights split across Decision Board, Steering Committee, and operational reporting
- Three separate funding models for different business realities
- A benefit framework covering financial, capacity, and risk/quality outcomes, with worked kill triggers
- A five-point handover checklist for the move into business-as-usual
What You'll Discover in the Whitepaper
- A two-lane intake funnel, with a fast-track for mandatory work
- Decision rights split across Decision Board, Steering Committee, and operational reporting
- Three separate funding models for different business realities
- A benefit framework covering financial, capacity, and risk/quality outcomes, with worked kill triggers
- A five-point handover checklist for the move into business-as-usual

What You'll Discover in the Whitepaper
All of these concepts are familiar, and most portfolios already run two or three of them well. The difficulty is that the value sits in the sequence. Intake decides what enters. Governance decides what stops. The value framework supplies evidence for both. The handover decides who is still accountable when that evidence arrives. Break the chain at any point, and the portfolio quietly reverts to drift.
All of these concepts are familiar, and most portfolios already run two or three of them well. The difficulty is that the value sits in the sequence. Intake decides what enters. Governance decides what stops. The value framework supplies evidence for both. The handover decides who is still accountable when that evidence arrives. Break the chain at any point, and the portfolio quietly reverts to drift.
All of these concepts are familiar, and most portfolios already run two or three of them well. The difficulty is that the value sits in the sequence. Intake decides what enters. Governance decides what stops. The value framework supplies evidence for both. The handover decides who is still accountable when that evidence arrives. Break the chain at any point, and the portfolio quietly reverts to drift.
Why It Matters
All of these concepts are familiar, and most portfolios already run two or three of them well. The difficulty is that the value sits in the sequence. Intake decides what enters. Governance decides what stops. The value framework supplies evidence for both. The handover decides who is still accountable when that evidence arrives. Break the chain at any point, and the portfolio quietly reverts to drift.
Why It Matters
All of these concepts are familiar, and most portfolios already run two or three of them well. The difficulty is that the value sits in the sequence. Intake decides what enters. Governance decides what stops. The value framework supplies evidence for both. The handover decides who is still accountable when that evidence arrives. Break the chain at any point, and the portfolio quietly reverts to drift.
Why It Matters
The whitepaper breaks down the full governance model: intake and prioritization criteria, decision rights, funding models, a value framework covering financial, capacity, and risk outcomes, and the kill triggers that let leaders stop work without stigma.

Curious how this applies to your own portfolio?
Reach out to our team - we're happy to talk it through. We've worked with organizations on these same governance gaps in data and AI portfolios, and can help you spot where yours might be exposed.
In this four-part series, “Mastering CX in Pharma”, we aim to share our perspective and approaches on how to succeed in designing a winning customer experience. We will deep dive into engagement model design, data as a key enabler, how to design an operating model that supports your strategic ambitions, and the role of change management.
Click to read more
In this four-part series, “Mastering CX in Pharma”, we aim to share our perspective and approaches on how to succeed in designing a winning customer experience. We will deep dive into engagement model design, data as a key enabler, how to design an operating model that supports your strategic ambitions, and the role of change management.
Click to read more
Sign up for the whitepaper and learn how Agentic AI is set to disrupt pharma’s commercial engagement - and why acting now is key to staying ahead. Explore how a strategic approach to AI adoption can help pharma scale impact, optimize operations, and unlock lasting value.
Click to read moreAI is revolutionizing the pharmaceutical industry, improving efficiency in drug discovery, clinical development, and customer engagement. Key applications like content creation, insights extraction, and predictive analytics streamline operations. To maximize AI’s potential, a strategic, holistic approach is crucial, avoiding siloed efforts and aligning with business goals for scalable success.
Click to read more

